Clinical Guides
Multiple Sclerosis: Relapse, Long-Term Treatment and Safety
A source-grounded guide to multiple sclerosis in adults, separating true relapse from infection or progression, using specialist-governed disease-modifying therapy, and planning symptom, vaccination, pregnancy and rehabilitation care in India.
MedNext Academy | 13 min read
Multiple Sclerosis: Relapse, Long-Term Treatment and Safety
A source-grounded guide to multiple sclerosis in adults, separating true relapse from infection or progression, using specialist-governed disease-modifying therapy, and planning symptom, vaccination, pregnancy and rehabilitation care in India.
Summary
Multiple sclerosis (MS) is an immune-mediated central nervous system disorder with relapsing and progressive courses. Management has two distinct aims: treat a disabling acute relapse safely, and reduce future inflammatory activity or progression through specialist-led disease-modifying therapy (DMT), rehabilitation, symptom care and risk-factor support. A relapse is new or worsening neurological symptoms lasting more than 24 hours, after at least one month of stability, with infection and other causes excluded. [current guidelines, recommendations 1.7.1–1.7.3.] Not every fluctuation needs steroids, and steroids do not replace DMT review.
Current guidelines recommends discussing a suspected relapse and steroid treatment with an MS-experienced clinician if the assessor is not a specialist. It recommends oral methylprednisolone 0.5 g daily for five days for a relapse that affects usual tasks, and intravenous methylprednisolone 1 g daily for three to five days only as an alternative when oral treatment fails/is not tolerated or admission and monitoring are needed. [current guidelines, recommendations 1.7.5–1.7.12.] These are exact UK guideline regimens, not a patient-held rescue prescription or a substitute for Indian local protocol, diabetes review and infection exclusion.
DMT choice is a specialist decision linked to MS phenotype, inflammatory activity, MRI, disability, previous treatment, pregnancy plans, infection risk, vaccination, laboratory monitoring and access. Current guidelines lists individual technology appraisals rather than a universal DMT schedule. [current guidelines, recommendations 1.8.1–1.8.10.] Every person needs a named neurology team, a comprehensive review and a written action plan for new symptoms, relapse, pregnancy and adverse effects.
How Common Is It?
MS is less common in India than in many northern-latitude populations, but this guide does not attach a national prevalence figure without a current population source. The practical burden is still substantial: recurrent relapses, visual and sensory symptoms, weakness, spasticity, fatigue, bladder dysfunction, cognitive change, depression and work or family disruption can accumulate even when appointments are spaced apart. Disease activity and disability are individual, not determined by a headline number.
A local service should measure what it can improve: delay from a new neurological symptom to expert advice, infection screening before steroid treatment, access to MRI and rehabilitation, DMT interruptions, vaccination and pregnancy counselling, emergency admissions, symptom burden and missed follow-up. WHO-style service metrics are not enough if patients cannot obtain monitoring, infusions, blood tests or a place to contact during a suspected relapse.
Current guidelines describes a comprehensive MS review spanning disease course, relapses, active disease, DMT eligibility, disability, general health, social participation, carers and medicines. [current guidelines, comprehensive review recommendations 1.6.1–1.6.6.] That structure is more useful than guessing a local epidemiological rate.
In India, uneven neurology access, high out-of-pocket cost, distance to MRI or infusion centres, and fragmented care between public and private systems can turn a manageable relapse or DMT monitoring problem into disability. Document these barriers early and plan shared care rather than assuming a tertiary-centre pathway is accessible.
Risk Factors
Clinical risk includes prior inflammatory activity, untreated or interrupted active disease, poor access to specialist review, infection, smoking, immobility, falls, depression, untreated bladder dysfunction and medication adverse effects. Current guidelines advises people with MS not to smoke because smoking increases disability progression, and encourages regular exercise because it may benefit MS without harmful effects on the disease. [current guidelines, recommendations 1.4.1–1.4.2.] Exercise should be individually adapted, not prescribed as proof that symptoms are psychological.
For relapse assessment, infection is a leading confounder. Current guidelines requires urinary and respiratory infection to be ruled out before diagnosing relapse. [current guidelines, recommendation 1.7.2.] Fever, dysuria, cough, new medicines, heat, sleep deprivation and worsening baseline symptoms may produce pseudo-relapse or fluctuation. A prior diagnosis of MS must not prevent assessment for stroke, spinal compression, migraine, seizure, metabolic disturbance or medication toxicity.
DMT-related risk is agent-specific. Infection susceptibility, vaccination timing, pregnancy exposure, blood-count or liver monitoring, infusion reactions and malignancy or opportunistic-infection surveillance cannot be generalised across the class. Current guidelines directs clinicians to individual technology appraisals for each DMT. [current guidelines, section 1.8.] Therefore no drug should be started, stopped, switched or “held for infection” from a generic patient leaflet.
Ask proactively about family planning. Current guidelines recommends asking about plans for pregnancy or family extension soon after diagnosis and at regular intervals, and says people using DMTs should tell their healthcare professional when trying to conceive or when pregnant. [current guidelines, recommendations 1.2.11–1.2.13.]
Diagnosis
Diagnosis of MS and assessment of a new event are specialist neurological tasks. This guide focuses on recognising a possible relapse and excluding time-critical alternatives. A labelled “relapse” should have a symptom timeline, objective change where possible, infection screen, functional impact and a record of communication with the MS team.
History
Ask about new or worsening vision loss, diplopia, sensory disturbance, weakness, imbalance, gait change, bladder/bowel symptoms, pain, fatigue, cognition and speech; establish onset, duration and whether symptoms persist beyond 24 hours after a stable month. Ask about fever, dysuria, cough, viral symptoms, medication changes, heat exposure, sleep, pregnancy, recent vaccination and substance use. Determine whether symptoms affect work, mobility, self-care, driving or safety.
Examination
Document conscious level, visual acuity where feasible, eye movements, power, tone, reflexes, sensation, coordination, gait, bladder retention concerns and functional baseline. Look for red flags such as abrupt maximal deficit, severe headache, altered consciousness, fever, meningism, severe back pain or a sensory level. These may require an emergency pathway rather than routine MS follow-up.
Investigations
Testing is question-led. Before steroid treatment, assess for infection—especially urinary or respiratory infection—as Current guidelines directs. [current guidelines, recommendation 1.7.2.] Urinalysis, cultures, blood tests, MRI or other studies should be selected by symptoms and specialist advice. Do not postpone emergency stroke, cord-compression or sepsis assessment while arranging MS imaging. A routine MRI does not by itself prove that a symptom is a relapse; clinical history, examination and alternative causes matter.
Differential Diagnosis
Differentiate relapse from pseudo-relapse, progression and unrelated acute illness. A pseudo-relapse is transient worsening of established symptoms with a trigger such as infection, fever or heat; treating the trigger may be more important than steroids. current guidelines specifically requires ruling out urinary and respiratory infection and distinguishing relapse from disease fluctuations or progression. [current guidelines, recommendations 1.7.1–1.7.3.]
Abrupt focal deficits may represent stroke or seizure; severe headache or altered consciousness may reflect infection, haemorrhage or another neurological emergency; progressive weakness or a sensory level may require urgent spinal assessment. New confusion, agitation, insomnia or hyperglycaemia may be steroid related if treatment has already started. Do not normalise dangerous symptoms because the person has MS.
Progression is typically gradual worsening over months rather than a discrete inflammatory episode. New symptoms lasting beyond three months should not routinely be labelled a relapse under current guidelines guidance. [current guidelines, recommendation 1.7.3.] This distinction affects DMT review, rehabilitation, social support and whether high-dose steroids are likely to help.
Medication adverse effects and mental-health conditions can coexist with MS. Fatigue may arise from sleep disorder, depression, anaemia, infection, pain, medicine burden or activity limitation. A good differential names the likely mechanism, excludes urgent alternatives and sets a review point rather than offering reflex steroids or a new symptom medicine.
Management
Provide a local pathway for people to report new symptoms promptly. Current guidelines recommends assessing and offering treatment as early as possible, within 14 days of symptom onset, when a relapse affects usual tasks, and says non-specialists should discuss diagnosis and steroids with an MS expert because not all relapses require steroid treatment. [current guidelines, recommendations 1.7.4–1.7.6.] Record onset, function, infection assessment, baseline disability and the decision-maker.
For an eligible relapse, current guidelines recommends oral methylprednisolone 0.5 g daily for five days. It allows intravenous methylprednisolone 1 g daily for three to five days only when oral therapy has failed or is not tolerated, or when a severe relapse requires admission or medical/psychological monitoring. [current guidelines, recommendations 1.7.7–1.7.9.] Do not give a standing home supply for future self-administration; current guidelines expressly advises against it. [current guidelines, recommendation 1.7.10.] Discuss insomnia, mood change, confusion, agitation and worsened glucose control, especially in diabetes. [current guidelines, recommendations 1.7.11–1.7.13.]
Notify the MS multidisciplinary team because relapse frequency may change DMT choice. [current guidelines, recommendation 1.7.14.] DMT initiation, switching, interruption, infection management, vaccine timing and pregnancy planning must remain with specialist neurology and the specific drug’s current product information. Rehabilitation, occupational therapy, continence, physiotherapy, mental-health and social-care support should run alongside—not after—the medication decision.
For severe relapse or unmet medical/social needs at home, current guidelines advises inpatient treatment. [current guidelines, recommendations 1.7.15–1.7.18.]
Prescribing Information
High-dose steroids are a defined relapse treatment, not a universal response to fatigue or a patient-directed emergency pack. The exact current guidelines regimens are oral methylprednisolone 0.5 g daily for five days, or IV methylprednisolone 1 g daily for three to five days only in the specified alternative circumstances. [current guidelines, recommendations 1.7.7–1.7.9.] Verify infection exclusion, diabetes plan, psychiatric history, blood pressure, current medicines, pregnancy context, formulation and monitoring in the local protocol before prescribing.
Current guidelines advises against lower steroid doses for acute relapse and against issuing steroids for future self-administration. [current guidelines, recommendations 1.7.9–1.7.10.] Counsel on temporary insomnia, depression, confusion, agitation and worsened glucose control. [current guidelines, recommendation 1.7.12.] Record an emergency contact and a post-treatment review, rather than leaving the patient to judge treatment failure alone.
DMT prescribing is specialist-governed. Current guidelines lists technology appraisals for individual agents across relapsing and active progressive disease, not one interchangeable regimen. [current guidelines, section 1.8.] Each drug’s infection screen, live-vaccine advice, blood tests, contraception/pregnancy plan, cancer surveillance, infusion or injection monitoring and discontinuation strategy must be taken from the current approved label and specialist protocol. India-specific availability and reimbursement may restrict choice; never substitute a different DMT without the MS team.
Symptom medicines require the same discipline. Treat pain, spasticity, bladder symptoms, fatigue, mood and sleep after assessment of cause, falls, cognition, renal function, pregnancy and interactions. Use the current local formulary and the relevant specialist pathway; this guide intentionally does not invent a dose or drug sequence for heterogeneous symptoms.
When to Refer
Refer urgently for sudden severe neurological deficit, altered consciousness, severe headache, fever/meningism, suspected sepsis, new respiratory compromise, acute urinary retention, severe back pain with neurological signs, falls causing injury, or inability to manage safely at home. These may be emergencies unrelated to MS relapse.
Contact the MS/neurology team promptly for a suspected relapse lasting more than 24 hours, new visual loss, progressive gait decline, repeated relapses, new MRI activity, DMT interruption, significant DMT adverse effect, planned surgery, vaccination question, pregnancy planning, pregnancy, postpartum change or breastfeeding discussion. current guidelines asks clinicians to offer a comprehensive review and refer issues to the MS multidisciplinary team or other appropriate teams. [current guidelines, recommendations 1.6.1–1.6.6.]
Refer to rehabilitation, continence, physiotherapy, occupational therapy, speech and language therapy, neuropsychology, mental health and social services according to function. current guidelines says severe relapse or difficulty meeting medical and social needs at home can require inpatient care and social-care assessment. [current guidelines, recommendations 1.7.15–1.7.18.]
In India, referral planning should specify the nearest neurology centre, MRI/infusion access, emergency route, laboratory location, financial-authorisation steps and a local clinician responsible for routine monitoring. A referral without transport or contact details is not a safety plan.
Red Flags
Do not call every new symptom an MS relapse. Fever, dysuria, cough or other infection signs must prompt infection assessment first; current guidelines specifically highlights urinary and respiratory infection. [current guidelines, recommendation 1.7.2.] Abrupt weakness, facial droop, severe headache, seizure, reduced consciousness or a rapidly evolving sensory level need emergency assessment for vascular, infectious, seizure or spinal causes.
Steroid red flags include severe mood change, confusion, agitation, uncontrolled hyperglycaemia, inability to take oral medication, severe relapse requiring monitoring and infection discovered during assessment. Current guidelines identifies temporary mental-health effects and worsening glucose control as high-dose steroid complications. [current guidelines, recommendations 1.7.11–1.7.13.] Do not repeat a course without expert review.
DMT red flags are agent-specific but include serious infection, unexplained fever, new neurological or visual symptoms, significant blood-test abnormality, severe infusion/injection reaction, pregnancy exposure or unplanned interruption. Contact the prescribing MS service; do not “pause and restart” based on general internet advice.
Social red flags include unsafe transfers, carer collapse, domestic neglect, inability to obtain essential medicine or food, driving risk, recurrent falls and cognitive impairment affecting adherence. These need urgent multidisciplinary action as much as an MRI request.
Indian Clinical Context
MS care in India is constrained by uneven neurology, MRI, infusion, laboratory and rehabilitation access. A safe plan is transparent about what is available locally and what requires a tertiary centre. Do not imply that every DMT referenced in an international guideline is licensed, funded or obtainable in every Indian setting. Specialist choice should integrate phenotype, monitoring capacity, infection risk, pregnancy plans, cost and the patient’s ability to attend review.
The immediate relapse pathway should identify a local clinician who can assess infection and function, a neurologist who can confirm the steroid/DMT decision, and an emergency centre for severe symptoms. High-dose steroid treatment without glucose monitoring or follow-up may be unsafe in people with diabetes, depression or limited support. [current guidelines, recommendations 1.7.7–1.7.13.]
Vaccination requires coordination, not avoidance. Current guidelines recommends vaccination in accordance with JCVI and the Green Book for people with MS and carers. [current guidelines, recommendation 1.4.3.] In India, use the current national immunisation programme, infectious-disease guidance and the specific DMT protocol; timing and live-vaccine advice vary by treatment.
Pregnancy counselling should be early and repeated. current guidelines says MS should not prevent family planning, but medicine use may need change before and during pregnancy, and breastfeeding is safe unless certain DMTs are used. [current guidelines, recommendation 1.2.13.] Refer to neurology and obstetrics before changing treatment; never stop a DMT solely from this guide.
NMC Competency Mapping
This guide supports supervised integration of Neurology, Medicine, Pharmacology, Rehabilitation Medicine, Psychiatry, Community Medicine and AETCOM. Learners should recognise possible relapse, seek infection and emergency differentials, document disability and function, know the limits of non-specialist prescribing and communicate timely escalation. Exact NMC competency codes require confirmation from the current institutional curriculum ledger. [NMC, Competency Based Medical Education Curriculum, undergraduate portal.]
A case exercise should ask for a relapse timeline, urinary/respiratory infection screen, neurological examination, functional impact, pregnancy plan, current DMT and monitoring record. The learner must distinguish a disabling inflammatory relapse from chronic progression or pseudo-relapse and call the MS team before steroid selection.
A prescribing station should test source use: quote the exact methylprednisolone regimen from the current guideline, identify diabetes and mood monitoring, state that home self-administration is not recommended, and decline to prescribe or switch DMT without specialist governance. Symptom treatment requires a problem-specific assessment, not a generic medication list.
Professional practice includes shared decision-making, access and affordability discussion, employment and driving implications, carer assessment, confidentiality around fertility plans and coordination between neurology, obstetrics and primary care. The aim is sustained function and safe care transitions.
Key Exam Pearls for NEET PG
A relapse is new or worsening MS symptoms lasting over 24 hours after at least one month of stability, in the absence of infection or another cause. Rule out urinary and respiratory infection and distinguish relapse from fluctuation or progression. [current guidelines, recommendations 1.7.1–1.7.3.]
Not all relapses need steroids. For a relapse affecting usual tasks, current guidelines recommends oral methylprednisolone 0.5 g daily for five days; IV methylprednisolone 1 g daily for three to five days is an alternative only in specified circumstances. [current guidelines, recommendations 1.7.5–1.7.9.] Do not issue a future home steroid supply.
Steroids may cause temporary insomnia, depression, confusion, agitation and worse glycaemic control. [current guidelines, recommendations 1.7.11–1.7.13.] DMTs are specialist-selected, agent-specific treatments—not acute-relapse steroids—and pregnancy, infection, vaccine and monitoring decisions need the individual protocol.
Exercise is encouraged; smoking increases disability progression. Family planning should be discussed regularly, and vaccination follows the applicable programme plus DMT-specific advice. [current guidelines, recommendations 1.2.11–1.2.13 and 1.4.1–1.4.3.]
Frequently Asked Questions
What symptoms define a possible multiple sclerosis relapse?
New or worsening neurological symptoms lasting more than 24 hours after a stable period of at least one month may be a relapse, but urinary and respiratory infection and other causes must first be excluded. Contact the MS team rather than self-starting steroids. [current guidelines, recommendations 1.7.1–1.7.6.]
What steroid regimen is recommended for an eligible MS relapse?
Current guidelines recommends oral methylprednisolone 0.5 g daily for five days. IV methylprednisolone 1 g daily for three to five days is reserved for oral failure/intolerance or severe relapse needing admission or monitoring. This requires local-protocol verification and specialist discussion. [current guidelines, recommendations 1.7.7–1.7.9.]
Can disease-modifying therapy be stopped when planning pregnancy or an infection?
Do not stop, switch or restart a DMT without the prescribing MS team. Pregnancy planning, infection risk, vaccination and monitoring are drug-specific. current guidelines asks people using DMTs to inform their healthcare professional promptly if trying to conceive or pregnant. [current guidelines, recommendations 1.2.11–1.2.13 and section 1.8.]
Why is rehabilitation part of MS treatment rather than an optional extra?
MS affects mobility, function, cognition, mood, continence and participation. Current guidelines requires comprehensive review and referral of identified issues to MS multidisciplinary and appropriate teams; rehabilitation and social care are part of relapse and long-term management. [current guidelines, recommendations 1.6.1–1.6.6 and 1.7.15–1.7.18.]
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic